Evotec (EVO) to Announce Earnings on Thursday

Evotec (NASDAQ:EVO) is expected to issue its Q2 2026 resultson Thursday, August 13th. Analysts expect the company to post earnings of ($0.0461) per share and revenue of $173.97 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 6:00 AM ET.

Evotec Stock Performance

NASDAQ EVO opened at $2.10 on Wednesday. The company has a current ratio of 1.68, a quick ratio of 1.60 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average price of $2.43 and a 200 day moving average price of $2.83. Evotec has a 52 week low of $1.89 and a 52 week high of $4.27.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. TD Cowen lowered shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a report on Wednesday, July 15th. Berenberg Bank cut Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 16th. HC Wainwright dropped their target price on Evotec from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a research report on Tuesday, July 21st. Finally, Wall Street Zen cut Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $3.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd lifted its position in Evotec by 25.1% during the 4th quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock worth $57,000 after acquiring an additional 3,709 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the period. Bank of America Corp DE raised its stake in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Evotec in the fourth quarter worth about $40,000. Finally, LPL Financial LLC lifted its holdings in shares of Evotec by 25.1% during the fourth quarter. LPL Financial LLC now owns 94,625 shares of the company’s stock worth $291,000 after purchasing an additional 18,964 shares during the period. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.